12.04.19

Aldeyra Therapeutics Announces Topline Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

Source: Aldeyra Therapeutics

11.22.19

ProtoKinetix AAGP Dry Eye Therapy Program Launched

Source: ProtoKinetix

11.11.19

Novaliq and Jiangsu Hengrui Medicine Announce a Collaboration for Investigational NOV03 and CyclASol in China

Source: Novaliq

11.01.19

Oyster Point Pharma Announces Pricing of Initial Public Offering

Source: Oyster Point Pharma

10.11.19

Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Disease

Source: Harbour BioMed

08.28.19

OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113 in a Mouse Model of Dry Eye Disease

Source: OKYO Pharma

08.09.19

FDA Does Not Approve Kala Pharmaceuticals’ NDA for Dry Eye Disease Candidate

Source: Kala Pharmaceuticals

08.07.19

TopiVert Announces Topline Results from Phase 2b/3 Study of Dry Eye Disease Drug Candidate

Source: TopiVert

07.24.19

Oyster Point Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Disease

Source: Oyster Point Pharma

07.22.19

Glaukos Announces Global Licensing Agreement With Intratus, Maker of Noninvasive Drug Delivery Platform

Source: Glaukos

View more stories